荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02509 荃信生物-B

圣诞节休市 12-24 12:08:29

7.640

+0.240

+3.24%

最高7.640	最低7.390	成交量13.48万
今开7.400	昨收7.400	日振幅3.38%
总市值16.97亿	流通市值15.66亿	总股本2.22亿
成交额99.76万	换手率0.07%	流通股本2.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":7.64,"timestamp":1735013309015,"preClose":7.4,"halted":0,"volume":134800,"delay":0,"floatShares":204999999,"shares":222071600,"eps":-2.62432,"marketStatus":"圣诞节休市","marketStatusCode":7,"change":0.24,"latestTime":"12-24 12:08:29","open":7.4,"high":7.64,"low":7.39,"amount":997564,"amplitude":0.033784,"askPrice":7.88,"askSize":200,"bidPrice":7.3,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-2.100754727986579,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"listingDate":1710864000000,"adjPreClose":7.4,"openAndCloseTimeList":[[1735003800000,1735012800000]],"volumeRatio":3.707,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"2493201709","title":"新春策略会路演实录|荃信生物-B(02509)：研产销一体深筑护城河，聚焦自免传递确定性价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2493201709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493201709?lang=zh_cn&edition=full","pubTime":"2024-12-23 11:55","pubTimestamp":1734926159,"startTime":"0","endTime":"0","summary":"在本次盛会的路演中，荃信生物-B联席公司秘书兼董事会秘书胡衍保就公司发展现状、战略与现场投资者做了零距离面对面沟通。商业化产品方面，赛乐信是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗生物类似药，由华东医药负责国内销售。华东医药目前在皮科领域的产品矩阵已初步达成，针对不同疾病类型、不同年龄段、不同剂型的用药需求，均可以提供适宜的产品满足临床治疗所需。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2490944827","title":"荃信生物-B(02509)下跌11.38%，报8.88元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490944827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490944827?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:57","pubTimestamp":1733983061,"startTime":"0","endTime":"0","summary":"12月12日，荃信生物-B(02509)盘中下跌11.38%，截至13:57，报8.88元/股，成交103.87万元。江苏荃信生物医药股份有限公司的主营业务是研发自身免疫及过敏性疾病的生物疗法。公司现有1个品种BLA已受理，1个品种处于临床3期，4个品种分别处于临床2期及1期，产品覆盖皮肤、风湿、呼吸、消化等领域，拥有及申报的国内外专利达90余项。截至2024年中报，荃信生物-B营业总收入4491.9万元、净利润-1.72亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12135746305804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2490822337","title":"荃信生物－Ｂ(02509)股价显著下跌10.878%，现价港币$8.93","url":"https://stock-news.laohu8.com/highlight/detail?id=2490822337","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490822337?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:52","pubTimestamp":1733982720,"startTime":"0","endTime":"0","summary":"[下跌股]荃信生物－Ｂ(02509) 股价在下午01:52比前收市价显著下跌10.878%，现股价为港币$8.93。至目前为止，今日最高价为$9.82，而最低价为$8.93。总成交量为10.52万股，总成交金额为港币$96.584万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD241212938/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2490884229","title":"荃信生物-B盘中异动 股价大跌5.59%报9.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884229","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490884229?lang=zh_cn&edition=full","pubTime":"2024-12-11 15:23","pubTimestamp":1733901829,"startTime":"0","endTime":"0","summary":"2024年12月11日下午盘15时23分，荃信生物-B股票出现异动，股价急速跳水5.59%。截至发稿，该股报9.800港元/股，成交量1000股，换手率0.00%，振幅0.00%。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.72%。其相关个股中，科济药业-B、思路迪医药股份、歌礼制药-B涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、思路迪医药股份，振幅分别为45.77%、37.91%、17.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211152349a1e57c14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211152349a1e57c14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2490069555","title":"荃信生物-B(02509)：薛明宇辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2490069555","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490069555?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:31","pubTimestamp":1733819486,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，非执行董事薛明宇因其个人事务需要投入更多时间，已提出辞任公司非执行董事及战略发展委员会成员之职务，自2024年12月10日起生效。薛博士将担任公司顾问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2490056824","title":"荃信生物-B盘中异动 股价大跌5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490056824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490056824?lang=zh_cn&edition=full","pubTime":"2024-12-10 11:47","pubTimestamp":1733802474,"startTime":"0","endTime":"0","summary":"2024年12月10日临近午盘11时47分，荃信生物-B股票出现波动，股价急速跳水5.46%。截至发稿，该股报10.380港元/股，成交量1.24万股，换手率0.01%，振幅5.46%。荃信生物-B股票所在的生物技术行业中，整体跌幅为1.02%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210114755ab6ba90f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210114755ab6ba90f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2490932737","title":"荃信生物-B盘中异动 早盘股价大跌6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490932737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490932737?lang=zh_cn&edition=full","pubTime":"2024-12-09 10:42","pubTimestamp":1733712158,"startTime":"0","endTime":"0","summary":"2024年12月09日早盘10时42分，荃信生物-B股票出现异动，股价急速下挫6.78%。截至发稿，该股报11.000港元/股，成交量9600股，换手率0.00%，振幅6.78%。荃信生物-B股票所在的生物技术行业中，整体涨幅为1.47%。其相关个股中，永泰生物-B、云康集团、圣诺医药-B涨幅较大，振幅较大的相关个股有永泰生物-B、晶泰科技、北海康成-B，振幅分别为18.33%、14.86%、14.29%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209104238a1df2d4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209104238a1df2d4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2488156892","title":"“立根中国资产·破岩2025”第九届智通财经资本市场年会活动报名中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2488156892","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488156892?lang=zh_cn&edition=full","pubTime":"2024-12-04 15:43","pubTimestamp":1733298208,"startTime":"0","endTime":"0","summary":"12月11日上午9：00-12:00：第九届智通财经资本市场年会暨上市公司颁奖典礼汇聚国内外顶尖金融机构代表与首席经济学家，300+港美股上市公司高管，共议资本市场投资热点话题，共同剖析大变局下资产价值波动的逻辑动因，把脉2025年中国资产投资机遇。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09885","00003","00855","01783","09878","00826","00033","01672","00363","00086","00992","01969","00666","06830","03709","01907","00857","06633","01651","09955","09860","06682","02498","06821","00020","09959","01313","09919","00861","02858","02362","02190","03877","02105","01378","00552","02158","03700","03306","06680","02273","01773","02509","02411","01083","01450","09616","01600","02268","01117"],"gpt_icon":0},{"id":"1142888850","title":"异动解读 | 荃信生物(02509.HK)QX001S产品线获扩展 股价大涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142888850","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142888850?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:26","pubTimestamp":1733218002,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509.HK)今日盘中股价大涨5.38%,引发市场关注。\n\n公司公布,其重磅产品QX001S用于儿童斑块状银屑病的补充申请获得受理。QX001S是公司自主研发的乌司奴单抗生物类似药,用于治疗银屑病。该药物于去年10月已获批上市用于成人中重度斑块状银屑病治疗,为国内首个获批的同类产品。\n\n本次儿童适应症的补充申请获受理,意味着荃信生物在银屑病治疗领域产品线将进一步丰富,市场规模扩大。 QX001S的成人和儿童适应症批准有望进一步推动公司主营业务发展,提升市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02509"],"gpt_icon":0},{"id":"2488959687","title":"港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488959687","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488959687?lang=zh_cn&edition=full","pubTime":"2024-12-03 13:52","pubTimestamp":1733205161,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超5%，截至发稿，涨5.57%，报11.38港元，成交额73.66万港元。消息面上，12月2日，华东医药全资子公司杭州中美华东制药有限公司收到国家药品监督管理局签发的《受理通知书》，由中美华东申报的乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获得受理。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 荃信生物-B(02509)涨超5% 乌司奴单抗注射液新适应症补充申请获NMPA受理","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2488930894","title":"荃信生物-B盘中异动 急速上涨5.57%报11.380港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488930894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488930894?lang=zh_cn&edition=full","pubTime":"2024-12-03 11:27","pubTimestamp":1733196470,"startTime":"0","endTime":"0","summary":"2024年12月03日早盘11时27分，荃信生物-B股票出现波动，股价快速上涨5.57%。截至发稿，该股报11.380港元/股，成交量4.78万股，换手率0.02%，振幅4.64%。资金方面，该股资金流入48.6756万港元，流出1.3168万港元。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，晶泰科技、云顶新耀-B、思路迪医药股份涨幅较大，振幅较大的相关个股有云顶新耀-B、晶泰科技、帝王国际投资，振幅分别为16.87%、15.68%、13.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203112750971b4676&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203112750971b4676&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2488603928","title":"荃信生物(02509.HK)QX001S用于儿童斑块状银屑病补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488603928","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488603928?lang=zh_cn&edition=full","pubTime":"2024-12-03 00:03","pubTimestamp":1733155380,"startTime":"0","endTime":"0","summary":"荃信生物－Ｂ(02509.HK) 公布，QX001S用于儿童斑块状银屑病的补充申请获得受理。QX001S由中美华东与公司共同推进III期临床试验研发，于2024年10月获批，用于治疗成年中重度斑块状银屑病，是国内首个获批的乌司奴单抗注射液生物类似药。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240312084302039_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240312084302039_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401213/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2488987677","title":"荃信生物-B：QX001S(乌司奴单抗注射液)用于儿童斑块状银屑病的补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488987677","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488987677?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:27","pubTimestamp":1733149621,"startTime":"0","endTime":"0","summary":"于2024年12月2日，QX001S用于儿童斑块状银屑病的补充申请获得受理。此次获得乌司奴单抗注射液儿童斑块状银屑病适应症补充申请受理通知书，是该款药品研发进程中的又一重要进展，长期有利于提升产品覆盖人群，进一步提升公司在自免治疗领域的核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223235abf00143&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223235abf00143&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2488746406","title":"荃信生物-B(02509)：QX001S(乌司奴单抗注射液)用于儿童斑块状银屑病的补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488746406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488746406?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:06","pubTimestamp":1733148374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 发布公告，于2024年12月2日，QX001S用于儿童斑块状银屑病的补充申请获得受理。近日，中美华东递交乌司奴单抗注射液用于儿童斑块状银屑病的补充申请获得受理。此次获得乌司奴单抗注射液儿童斑块状银屑病适应症补充申请受理通知书，是该款药品研发进程中的又一重要进展，长期有利于提升产品覆盖人群，进一步提升公司在自免治疗领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2487588587","title":"港股异动 | 荃信生物-B(02509)涨超6% 乌司奴单抗注射液上市许可申请此前获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2487588587","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487588587?lang=zh_cn&edition=full","pubTime":"2024-11-29 14:28","pubTimestamp":1732861706,"startTime":"0","endTime":"0","summary":"消息面上，荃信生物此前公布，11月5日，中美华东收到国家药品监督管理局核准签发的《药品注册证书》，由中美华东申报的乌司奴单抗注射液的上市许可申请获得批准，用于治疗成年中重度斑块状银屑病。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2487873304","title":"荃信生物-B盘中异动 下午盘股价大涨6.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487873304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487873304?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:07","pubTimestamp":1732856874,"startTime":"0","endTime":"0","summary":"2024年11月29日下午盘13时07分，荃信生物-B股票出现异动，股价快速上涨6.67%。截至发稿，该股报11.200港元/股，成交量1.26万股，换手率0.01%，振幅4.76%。荃信生物-B股票所在的生物技术行业中，整体涨幅为2.18%。其相关个股中，东曜药业-B、荃信生物-B、百济神州涨幅较大，振幅较大的相关个股有晶泰科技、来凯医药-B、宜明昂科-B，振幅分别为10.20%、7.80%、7.07%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130754971a92d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130754971a92d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2486842079","title":"生物医药股多数走高！机构看好板块修复空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2486842079","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486842079?lang=zh_cn&edition=full","pubTime":"2024-11-27 18:37","pubTimestamp":1732703861,"startTime":"0","endTime":"0","summary":"11月27日，港股多数生物医药股走强。其中，科伦博泰生物-B(06990.HK)大涨10.11%，诺诚健华(09969.HK)涨8.93%，荃信生物-B（02509.HK）涨8.57%，科济药业-B（02171.HK）涨7.73%，百济神州（06160.HK）涨7.21%，金斯瑞生物科技（01548.HK）涨4.96%。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202411_1/1cfe0a94-093d-40f9-9aa9-6ac7e40e346c.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202411_1/1cfe0a94-093d-40f9-9aa9-6ac7e40e346c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6746f675bde0b3216fc904f4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["US10Y.BOND","BK1161","BK4550","BK4585","BK4534","06990","BK1588","US6M.BOND","US7Y.BOND","OEF","06160","SDS","HK0000306685.HKD",".SPX","US30Y.BOND","BK1583","US3Y.BOND","US5Y.BOND","HK0000320223.HKD","UPRO","OEX","BK4077","02171","BK4588","SPY","BK1585","US12M.BOND","SSO","BK1500","BK1587","BK4581","BK1574","BK1576","FOMC","US2Y.BOND","ESmain","HK0000934320.USD","IVV","09969","LU1969619763.USD","02509","01548","SPXU","LU0588546209.SGD","HK0000306701.USD","SH","LU0196878994.USD","LU2328871848.SGD","BK4504","BK1141"],"gpt_icon":0},{"id":"1174581776","title":"异动解读 | 荃信生物-B股价盘中大涨8.57%,估值较低获做多力道","url":"https://stock-news.laohu8.com/highlight/detail?id=1174581776","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174581776?lang=zh_cn&edition=full","pubTime":"2024-11-27 14:54","pubTimestamp":1732690474,"startTime":"0","endTime":"0","summary":"生物技术股荃信生物-B今日盘中股价大涨8.57%,股价一度触及11.32港元,成交量及换手率均较平日呈现明显上升。不过需留意的是,公司财报也同时显示上一个会计年度仍然亏损,净利润为-1.89亿港元,每股亏损0.87港元,短期内能否扭亏为盈仍存在不确定性。市场对其未来发展前景存在乐观预期,但投资者亦需审慎评估公司的实际经营状况及行业竞争格局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 荃信生物-B股价盘中大涨8.57%,估值较低获做多力道","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02509"],"gpt_icon":0},{"id":"2486702890","title":"荃信生物-B盘中异动 下午盘快速拉升7.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486702890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486702890?lang=zh_cn&edition=full","pubTime":"2024-11-27 14:30","pubTimestamp":1732689044,"startTime":"0","endTime":"0","summary":"2024年11月27日下午盘14时30分，荃信生物-B股票出现异动，股价急速拉升7.81%。截至发稿，该股报11.320港元/股，成交量3.3万股，换手率0.02%，振幅8.19%。荃信生物-B股票所在的生物技术行业中，整体涨幅为2.04%。其相关个股中，荃信生物-B、科伦博泰生物-B、诺诚健华涨幅较大，振幅较大的相关个股有科济药业-B、来凯医药-B、北海康成-B，振幅分别为19.83%、19.46%、16.15%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127143044abe27891&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127143044abe27891&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2486043584","title":"荃信生物-B盘中异动 股价大涨5.11%报10.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486043584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486043584?lang=zh_cn&edition=full","pubTime":"2024-11-26 14:14","pubTimestamp":1732601686,"startTime":"0","endTime":"0","summary":"2024年11月26日下午盘14时14分，荃信生物-B股票出现波动，股价大幅上涨5.11%。截至发稿，该股报10.500港元/股，成交量2200股，换手率0.00%，振幅5.01%。资金方面，该股资金流入2.0256万港元，流出0港元。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，华康生物医学、圣诺医药-B、荃信生物-B涨幅较大，振幅较大的相关个股有北海康成-B、博安生物、晶泰科技，振幅分别为38.51%、26.12%、13.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112614144698e44956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112614144698e44956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.0521},{"period":"1month","weight":-0.1586},{"period":"3month","weight":-0.6749},{"period":"6month","weight":-0.6535},{"period":"1year","weight":-0.6141},{"period":"ytd","weight":-0.6141}],"compareEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0452},{"period":"3month","weight":0.0507},{"period":"6month","weight":0.1344},{"period":"1year","weight":0.23},{"period":"ytd","weight":0.179}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自身免疫及过敏性疾病生物疗法的生物科技研发。该公司业务主要涵盖四大疾病领域，包括皮肤、风湿、呼吸道及消化道疾病。该公司正在研发的项目有8个，目标适应症包括银屑病、特应性皮炎、类风湿性关节炎、炎症性肠病、哮喘等。该公司核心产品有QX002N和QX005N。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}